The aim of this study was to analyze the clinical outcomes after using an innovative implant system characterized by a modern platform-switched Morse taper connection and an osteo growth induction titanium surface (a particular type of SLA surface). Peri-implant bone loss (PBL) and implant success rate were examined after a 1- to 3-year follow-up.
The study was conducted as a cross-sectional analysis on all patients treated from January 2011 to December 2014 using CLC CONIC implants. Implants were divided into 3 main groups, based on the duration of the follow-up (1 year, 2 years, and 3 years), then subgrouped by diameter, length, and type of prosthetic rehabilitation to compare differences in PBL. X-rays were taken at the time of surgery, at prosthetic loading, at 1 year, and then annually thereafter. Previously-established success criteria were used to assess the implants. Frequency analyses and comparisons between the means (with 95% CI) were conducted for the statistical analysis of the data collected.
One hundred twenty patients met inclusion and exclusion criteria, and completed the follow-up, and were thus eligible for the study, with a total of 261 CLC CONIC implants. The mean follow-up was 22.45 months. No implants failed, giving an overall success rate of 100%. The average PBL at 1-year follow-up was 0.047 mm, at 2 years it was 0.128 mm, and at 3 years it was 0.236 mm.
The CLC CONIC implant system had a high success rate after 1 to 3 years of follow-up, in line with previous reports in the scientific literature. Combining platform switching with the Morse taper connection enabled stable bone levels to be achieved in the short to medium term.
*Centre for Integrative Biology (CIBIO), University of Trento, Trento
†IDIS (Institute for Dental & Implant Studies), Vicenza
§Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia
||Department of Neurosciences, University of Padova, Padova
¶Department of Health Sciences, “A. Avogadro” University of Eastern Piedmont, Novara
#CLC Scientific, Vicenza, Italy.
Address correspondence and reprint requests to Paolo Ghensi, DDS, Clin Msc, via Chini 101/2, 38123 Trento (TN), Italy; E-mail: email@example.com
Received 29 April, 2018
Accepted 23 May, 2018
Claudio Soldini declares a conflict of interest with the implant brand used in this clinical study as co-owner of the company CLC Scientific. The remaining authors report no conflicts of interest.